California's Vertos Medical has closed $23 million in financing, cash the company will use to expand the market for its pain-reducing spinal surgery device.
A U.K. study knocks the use of an angiogram on its own to diagnose and treat heart disease patients, blaming it for flawed results in at least 25% of all cases. Teaming it with a second diagnostic known as a fractional flow reserve could eliminate the problem, however, the trial finding concludes. Read more >>
While many of the big-time medical device companies are forecasting sunny earnings for 2013, that hasn't slowed down the march to trim payroll, as companies from Accuray to Zimmer have announced thousands of layoffs since Jan. 1.
Though the stated reasons always vary, underlying every layoff announcement--even the ones buried in paragraph 27 of otherwise cheery press releases--is an understanding that the business of selling medical devices and diagnostics has changed.
Icahn ally added to Forest board
Pursuant to an agreement with Carl Icahn and affiliated entities, Forest Laboratories' ($FRX) board of directors has appointed Vincent Intrieri as a new independent member of its board of directors. Intrieri sits on the boards of a number of companies, like Navistar International, in which Forest investor Carl Icahn has invested. Story
POPULAR COMMENT THREADS
Terumo is planning to hire 416 people in Northern Ireland, expanding the R&D operations at a plant that produces blood transfusion technologies.
Washington's Mirabilis Medica has closed $7 million in financing for its ultrasound-based uterine fibroid treatment, part of a Series A that could reach $13 million.
CryoLife won the FDA's blessing to kick off a U.S. trial of its PerClot bleeding-control device, plotting a large-scale study to snag U.S. approval.
OrthoSensor picked up FDA clearance for its latest limb-aligning technology for knee replacements, a device the company touts as cutting out the guesswork in orthopedic procedures.
Techne, a manufacturer of biological research products, has agreed to buy diagnostics outfit Bionostics for $104 million, a deal it expects to close early next year.
As medical device companies the world over race to develop an artificial pancreas, the Juvenile Diabetes Research Foundation has teamed up with Becton Dickinson to combine insulin infusion with continuous glucose monitoring and improve the lives of diabetics.
From Our Sister Sites
Gilead Sciences has recalled 20 batches of its antifungal drug AmBisome after bacterial contamination was discovered during a routine test at its plant in San Dimas, CA.
Researchers in the U.S., the U.K. and Australia have developed a biosensor nanotechnology that could improve drug delivery for the treatment of pancreatic cancer while allowing for imaging at the same time, according to a report in Asian Scientist .